If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarillion Plc Regulatory News (CLLN)

  • This share is currently suspended. It was suspended at a price of 14.27

Share Price Information for Carillion Plc (CLLN)

Share Price is delayed by 15 minutes
Get Live Data
14.27    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £61.40m
CLLN Live PriceLast checked at - London Stock Exchange

Intraday Carillion Plc Share Chart

Termination of Merger Discussions

31 Jul 2014 07:00

RNS Number : 8359N
Balfour Beatty PLC
31 July 2014
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

 

FOR IMMEDIATE RELEASE

 

 

31 July 2014

 

 

Termination of merger discussions by Balfour Beatty plc ('Balfour Beatty') with Carillion plc ('Carillion')

 

Balfour Beatty announces that it is terminating discussions with Carillion regarding a possible merger with immediate effect. The termination of discussions follows Carillion's wholly unexpected decision to only progress the possible merger in the event that Parsons Brinckerhoff remained part of the potential combined entity. This change is contrary to the basis upon which the Balfour Beatty Board agreed to engage in preliminary discussions. It is also contrary to the joint announcement released on 24 July 2014 which confirmed that the sale of Parsons Brinckerhoff would be unaffected by the merger discussions and also a presentation to Balfour Beatty's Board by Carillion on 28 July 2014. This change in the proposed terms is not acceptable to the Board of Balfour Beatty.

 

Balfour Beatty will proceed in accordance with its own business plan, including the competitive sale process of Parsons Brinckerhoff currently well underway. It will also continue to actively progress its search for a Group CEO.

 

Balfour Beatty confirms there is no material new information on trading since 3 July 2014 and will publish its interim results on 13 August 2014. 

 

This announcement, that Balfour Beatty has no intention to make an offer for Carillion, is made in accordance with Rule 2.8 of the Code. As a result of this announcement Balfour Beatty will be bound by the restrictions contained in Rule 2.8 of the Code. For the purposes of Rule 2.8 of the Code, Balfour Beatty reserves the right to make or participate in an offer for Carillion (and/or take any other action which would otherwise be restricted under Rule 2.8 of the Code) within the next six months following the date of this announcement in the circumstances set out in Note 2 of Rule 2.8 of the Code.

 

This announcement is not being made with the consent of Carillion.

 

 

Enquiries:

 

Balfour BeattyAnoop Kang, Head of Investor Relations+44 (0) 20 7216 6913

Patrick Kerr, Director of Corporate Communications+44 (0) 20 7963 4258

 

Maitland

Neil Bennett

Liz Morley

+44 (0) 20 7379 5151

 

Publication on website

 

A copy of this announcement will be made available subject to certain restrictions relating to persons resident in restricted jurisdictions on Balfour Beatty's website at www.balfourbeatty.com by no later than 12 noon (London time) on 1 August 2014.

 

The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OTTUASVRSWABORR
Date   Source Headline
3rd Apr 20187:30 amRNSUpdate re Liquidation of Carillion
19th Mar 20187:00 amRNSFRC investigation
17th Jan 20188:15 amRNSAnnouncement Re. Carillion PLC
15th Jan 20187:45 amRNSSuspension - Carillion PLC
15th Jan 20187:00 amRNSCompulsory liquidation of Carillion
12th Jan 20186:08 pmRNSUpdate on discussions with creditors
12th Jan 20185:08 pmRNSHolding(s) in Company
10th Jan 20185:48 pmRNSHolding(s) in Company
9th Jan 20187:03 amRNSResponse to share price movement
3rd Jan 20184:44 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSRegulatory investigation
22nd Dec 20177:00 amRNSUpdate on financial covenant deferral
20th Dec 201710:16 amRNSBlock listing Interim Review
20th Dec 20177:00 amRNSChief Executive Appointment
13th Dec 20177:00 amRNSUpdate on UK healthcare facilities business
11th Dec 20177:58 amRNSHolding(s) in Company
1st Dec 20177:00 amRNSDirectorate Change
23rd Nov 201712:08 pmRNSHolding(s) in Company
22nd Nov 201712:29 pmRNSHolding(s) in Company
21st Nov 20174:11 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSFramework Award
17th Nov 20177:02 amRNSUpdate
15th Nov 20177:00 amRNSOman - letter of award for contract
6th Nov 20177:00 amRNSContract wins
2nd Nov 20177:00 amRNSDirectorate Change
31st Oct 20177:00 amRNSDisposal
27th Oct 20177:00 amRNSChief Executive Appointment
24th Oct 20177:00 amRNSUpdate on financing, disposals and work winning
12th Oct 201712:43 pmRNSUK Healthcare business
4th Oct 20172:58 pmRNSHolding(s) in Company
29th Sep 20177:00 amRNSHalf-year Report
22nd Sep 20171:00 pmRNSHolding(s) in Company
19th Sep 20174:55 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:17 pmRNSAnnouncement of 2017 interim results
17th Aug 20174:19 pmRNSHolding(s) in Company
15th Aug 20175:58 pmRNSHolding(s) in Company
11th Aug 20176:20 pmRNSHolding(s) in Company
8th Aug 20173:59 pmRNSHolding(s) in Company
8th Aug 201710:02 amRNSHolding(s) in Company
3rd Aug 20179:02 amRNSHolding(s) in Company
1st Aug 201712:24 pmRNSHolding(s) in Company
31st Jul 20172:57 pmRNSHolding(s) in Company
27th Jul 20176:28 pmRNSHolding(s) in Company
18th Jul 201710:49 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSCarillion JV awarded two further HESTIA contracts
17th Jul 20177:19 amRNSHS2 Contract Award
17th Jul 20177:00 amRNSCarillion appoints EY to support strategic review
14th Jul 201712:20 pmRNSHolding(s) in Company
14th Jul 20177:00 amRNSAppointment of Joint Financial Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.